Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
- DOI
- 10.2217/fon-2021-0598
- Published
- 2021 Oct 1
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2217/fon-2021-0598,
title = {Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.},
author = {Oaknin A and Tinker AV and Gilbert L and Samouëlian V and Mathews C and Brown J and Barretina-Ginesta MP and Moreno V and Gravina A and Abdeddaim C and Banerjee S and Guo W and Danaee H and Im E and Sabatier R},
year = {2021},
journal = {Future oncology (London, England)},
doi = {10.2217/fon-2021-0598},
url = {https://doi.org/10.2217/fon-2021-0598}
}RIS
TY - JOUR TI - Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. AU - Oaknin A AU - Tinker AV AU - Gilbert L AU - Samouëlian V AU - Mathews C AU - Brown J AU - Barretina-Ginesta MP AU - Moreno V AU - Gravina A AU - Abdeddaim C AU - Banerjee S AU - Guo W AU - Danaee H AU - Im E AU - Sabatier R PY - 2021 JO - Future oncology (London, England) DO - 10.2217/fon-2021-0598 UR - https://doi.org/10.2217/fon-2021-0598 ER -
APA
A, O., AV, T., L, G., V, S., C, M., J, B., MP, B., V, M., A, G., C, A., S, B., W, G., H, D., E, I., & R, S. (2021). Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.. Future oncology (London, England). https://doi.org/10.2217/fon-2021-0598
Source records
- pubmed · retrieved 2026-09-25T08:43:23.127Z